Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis to showcase new phase III data at ASCO

Novartis to showcase new phase III data at ASCO

1st June 2011

Novartis has announced plans to present new clinical trial data at the forthcoming annual meeting of the American Society of Clinical Oncology (ASCO).

The company will be highlighting data from a total of 140 abstracts – including results from phase III trials and beyond – at the medical conference, which takes place in Chicago between June 3rd and 7th 2011.

This will include phase III data examining the benefits of the leukaemia drug Glivec as an adjuvant treatment, with further phase III results from two pivotal trials of the developmental myelofibrosis therapy INC424.

Meanwhile, phase IV results will be showcased to support Afinitor's benefits as an advanced renal cell carcinoma treatment.

Herve Hoppenot, president for Novartis Oncology, said: "Our broad and deep portfolio of development programs gives us multiple opportunities to further advance treatments for the millions of patients and their families affected by these diseases."

Last month, the company achieved a milestone after receiving US approval for Afinitor as a treatment for advanced pancreatic neuroendocrine tumours, an indication for which it is also seeking European regulatory backing.ADNFCR-8000103-ID-800563184-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.